Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells
1996

Measuring NADH: Cytochrome b5 Reductase Activity in Human Tumor Cells

Sample size: 22 publication Evidence: moderate

Author Information

Author(s): HM Barham, R Inglis, EC Chinjel, IJ Stratford

Primary Institution: MRC Radiobiology Unit, Chilton, Didcot, Oxon, UK; Pharmacy Department, University of Manchester, Oxford Road, Manchester, UK

Hypothesis

The study aims to develop a validated assay for measuring the activity of NADH: cytochrome b5 reductase in human tumor cells to assess its role in activating bioreductive drugs.

Conclusion

The developed spectrophotometric assay provides a more accurate measure of cytochrome b5 reductase activity, revealing significant variations in activity across different human tumor cell lines.

Supporting Evidence

  • The assay revealed a 7-fold variation in cytochrome b5 reductase activity across different human tumor cell lines.
  • Using p-hydroxymercuribenzoate as an inhibitor allowed for a more accurate measurement of the enzyme's activity.
  • Previous methods for measuring cytochrome b5 reductase activity were found to be inaccurate, either overestimating or underestimating the enzyme's activity.

Takeaway

Scientists created a new test to measure an important enzyme in cancer cells that helps activate certain drugs, and they found that different cancer cells have different amounts of this enzyme.

Methodology

The study involved developing a spectrophotometric assay using p-hydroxymercuribenzoate to measure the pHMB-inhibitable NADH-dependent reduction of cytochrome c in tumor cell lysates.

Potential Biases

Potential bias exists due to the assumption that cytochrome b5 reductase is the only enzyme responsible for the NADH-dependent reduction of cytochrome c.

Limitations

The assay may not account for all reductase activities contributing to cytochrome c reduction, and the presence of other enzymes could affect the results.

Participant Demographics

The study involved a panel of 22 human tumor cell lines from various origins, including breast cancer and non-small cell lung cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication